Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
JAMA Neurol. 2020 May 1;77(5):582-592. doi: 10.1001/jamaneurol.2019.5125.
JAMA Neurol. 2020.
PMID: 32065623
Free PMC article.
Clinical Trial.
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
Fichtner ML, Hoarty MD, Vadysirisack DD, Munro-Sheldon B, Nowak RJ, O'Connor KC.
Fichtner ML, et al. Among authors: hoarty md.
PLoS One. 2022 Mar 15;17(3):e0264489. doi: 10.1371/journal.pone.0264489. eCollection 2022.
PLoS One. 2022.
PMID: 35290370
Free PMC article.
Item in Clipboard
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A.
Tang GQ, et al. Among authors: hoarty md.
Front Immunol. 2023 Aug 9;14:1213920. doi: 10.3389/fimmu.2023.1213920. eCollection 2023.
Front Immunol. 2023.
PMID: 37622108
Free PMC article.
Item in Clipboard
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A.
Tang GQ, et al. Among authors: hoarty md.
Front Immunol. 2023 Sep 25;14:1282155. doi: 10.3389/fimmu.2023.1282155. eCollection 2023.
Front Immunol. 2023.
PMID: 37818356
Free PMC article.
Item in Clipboard
Cite
Cite